Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2813160 | 0.97 | CTRB1 (0.33) | CTRB1DPP4 | |
| SCHEMBL4587279 | 0.89 | CTRB1 (0.44) | CTRB1 | |
| SCHEMBL4588260 | 0.87 | SLC15A2 (0.42) | — | |
| SCHEMBL2241981 | 0.87 | CTRB1 (0.44) | CTRB1 | |
| SCHEMBL17293240 | 0.87 | CTRB1 (0.37) | CTRB1 | |
| SCHEMBL3916119 | 0.87 | CTRB1 (0.37) | CTRB1 | |
| SCHEMBL29511173 | 0.87 | CTRB1 (0.37) | CTRB1 | |
| SCHEMBL749822 | 0.87 | CTRB1 (0.37) | CTRB1 | |
| SCHEMBL3810013 | 0.87 | CTRB1 (0.37) | CTRB1 | |
| SCHEMBL749821 | 0.87 | CTRB1 (0.37) | CTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255032-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN | PROCYTE CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
| US-7384916-B2 | Methods and compositions for preventing and treating aging or photodamaged skin | PROCYTE CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
| US-20060246029-A1 | Methods and compositions for preventing and treating aging or photodamaged skin | PROCYTE CORPORATION (US) | 2006-11-02 | — | — | US | disclosed |
| US-20060018851-A1 | Methods and compositions for preventing and treating hyperpigmentation of skin | PROCYTE CORPORATION (US) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060246029-A1 | Methods and compositions for preventing and treating aging or photodamaged skin | RBP1, RBP4, SOD1 | CTRB1 113/4885DPP4 2299/4885 |
| US-20060018851-A1 | Methods and compositions for preventing and treating hyperpigmentation of skin | RBP1, RBP4, MC1R | CTRB1 138/4885DPP4 2855/4885 |
| US-20080255032-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN | RBP1, RBP4, SOD1 | CTRB1 113/4885DPP4 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.